690
Participants
Start Date
January 24, 2022
Primary Completion Date
February 28, 2025
Study Completion Date
February 28, 2025
Brilaroxazine
RP5063, a new chemical entity (NCE), is a novel multimodal neuromodulator intended for treating schizophrenia and comorbid conditions. This drug is an investigational drug and has not been approved for treatment or marketing. RP5063 belongs to a class of third generation antipsychotics called Dopamine-Serotonin System Stabilizers. The chemical name of the RP5063 active pharmaceutical ingredient (API) is 6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo\[b\]\[1,4\]oxazin-3(4H)-one hydrochloride.
Placebo
RP5063 matching Placebo
RECRUITING
Reviva site, Gaithersburg
RECRUITING
Reviva site, Decatur
RECRUITING
Reviva site, Atlanta
RECRUITING
Reviva site, Miami Lakes
RECRUITING
Reviva site, Hollywood
RECRUITING
Reviva site, Hollywood
RECRUITING
Reviva site, Chicago
RECRUITING
Reviva site, Little Rock
RECRUITING
Reviva site, Bentonville
RECRUITING
Reviva site, Rogers
RECRUITING
Reviva site, Oklahoma City
RECRUITING
Reviva site, Richardson
RECRUITING
Reviva site, Austin
RECRUITING
Reviva site, Phoenix
RECRUITING
Reviva site, Riverside
RECRUITING
Reviva site, Garden Grove
RECRUITING
Reviva site, Lemon Grove
RECRUITING
Reviva site, Boston
Lead Sponsor
Reviva Pharmaceuticals
INDUSTRY